AI TRAINED ON LIVING SKIN TO DEVELOP NEW SKINCARE

Polansky's venture represents a convergence of artificial intelligence and biotech, using living tissue samples to accelerate skincare innovation. The approach involves maintaining human skin in laboratory conditions while training machine learning models to identify promising compounds and formulations. The methodology addresses a longstanding challenge in dermatology: testing skincare ingredients on viable tissue rather than relying solely on synthetic models or animal testing. By keeping skin alive outside the body, researchers can observe real biological responses to various compounds over extended periods. Polansky, who previously served as a top lieutenant to Sean Parker at Founders Fund, has been developing this technology quietly for years before the public disclosure. His background in startup strategy and technology development provided a foundation for building the AI-skincare intersection. The approach leverages machine learning to process data generated from living tissue experiments, potentially identifying skincare compounds faster than traditional research methods. AI models can recognize patterns in how skin responds to different ingredients, suggesting new combinations or formulations worth investigating further. This model aligns with broader industry trends toward more efficient drug and cosmetic discovery. Biotech companies increasingly use AI to reduce development timelines and costs while improving outcomes. The living tissue component distinguishes this approach from purely computational models. The startup emerges as cosmetic companies face mounting pressure to innovate faster while reducing reliance on animal testing. The European Union and other regions have implemented restrictions on animal testing in cosmetics, creating demand for alternative methods. Polansky's entry into biotech reflects a shift among prominent tech figures toward life sciences ventures. His public profile and connections position the startup to attract investment and partnerships within both technology and beauty industries. Details regarding the startup's current stage, funding, and commercialization timeline remain limited as the company begins public operations. The venture represents one of few known efforts combining large-scale tissue engineering with AI-driven compound discovery in cosmetics.